Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Peripheral Arterial Disease | Inflammation | Atherosclerosis of ExtremitiesThe Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion criteria:
1. Age \> 18 years
2. Symptomatic atherosclerotic LE PAD fulfilling at least one of the following:
a. Intermittent claudication with ankle/arm blood pressure ratio\* (ABI ≤ 0.90) or artery stenosis ≥ 50% plus one of i. \>1 vascular bed affected by atherosclerosis ii. Diabetes iii. Heart failure iv. Chronic kidney disease (eGFR \< 60 mL/min/1.73 m2)
b. Rest pain (mostly in foot) OR necrosis of limb OR gangrene of limb (corresponding to either Fontaine stages 3 or 4 OR Rutherford Classification categories 4 to 6). All must have an ankle/arm blood pressure ratio\* (ABI ≤ 0.90) OR artery stenosis ≥ 50%.
\* In cases of incompressible ankle arteries, the presence of toe pressure ≤ 60 mm Hg or toe-brachial index ≤ 0.70 is acceptable
c. Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty/stent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery
d. Leg or foot amputation for arterial vascular indications
3. Written or verbal informed consent from the patient
Exclusion Criteria:
1. Contraindication to colchicine
2. Long term requirement for colchicine for another clinical indication
3. Active diarrhoea
4. eGFR \< 30 mL/min/1.73 m2
5. Cirrhosis or severe chronic liver disease
6. Woman who is pregnant, or breast-feeding or of child-bearing potential not protected by reliable contraception or is planning conception during the study
7. Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (with the exception of azithromycin)
8. Patients who are deemed unlikely to return for follow-up
9. Patients with life expectancy \< 1 year
Study Location
Hamilton General Hospital
Hamilton General HospitalHamilton, Ontario
Canada
Contact Study Team
Michelle Zondag
905-527-4322Sunnybrook Research Institute
Sunnybrook Research InstituteToronto, Ontario
Canada
Contact Study Team
Leslie Summers deLuca
London Health Sciences Centre
London Health Sciences CentreLondon, Ontario
Canada
Contact Study Team
Teresa Novick
Corcare Cardiovascular Research Inc.
Corcare Cardiovascular Research Inc.Scarborough, Ontario
Canada
Contact Study Team
Bev Bozek
- Study Sponsored By
- Population Health Research Institute
- Participants Required
- More Information
- Study ID:
NCT04774159